Search
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigationalHIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens … [A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy _in vitro_, little to no cross-resistance with existing antiretroviral
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...
Synonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-oneNystatin
go.drugbank.com/drugs/DB00646ApprovedInvestigationalVet approved[L10686] It is one of the most effective antifungal agents synthesized by bacteria, in this case a strain of _Streptomyces noursei_,[L10776] and is closely related to [amphotericin B], differing only slightly … [A188562] As it undergoes very little absorption following oral or topical administration, nystatin's efficacy is limited to the treatment/prevention of cutaneous, mucocutaneous, and gastrointestinal fungal
Products: SN-NYSTATIN 4.4%W/W PREMIXVoclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalEarly intervention with voclosporin coupled with a kidney response is believed to prevent irreversible damage to the kidney and lead to better long-term clinical outcomes for patients with LN. … L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared to
Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalIt is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [L941]. … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered
Ataluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk.
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate.
Sotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34440] Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was … found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting.
alpha-Linolenic acid
go.drugbank.com/drugs/DB00132ApprovedInvestigationalNutraceuticalWithdrawnIt is a component of many common vegetable oils and is important to human nutrition.
Mixtures: Cavan One, Folcaps Care OneCysteine
go.drugbank.com/drugs/DB00151ApprovedInvestigationalNutraceuticalA thiol-containing non-essential amino acid that is oxidized to form cystine.
Mixtures: Aminoven Infant 10% w/v